BC genomic analysis reveals invasive lobular carcinoma subtypes

JohnSmith

New ILC paper. Published May 2016.

Lobular breast cancer: Clinical, molecular and morphological characteristics.
Christgen M1, Steinemann D2, Kühnle E3, Länger F4, Gluz O5, Harbeck N6, Kreipe H4.
Author info:
1Institute of Pathology, Hannover Medical School, Hannover, Germany. Email: Christgen DOT Matthias AT MH-Hannover.de
2Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
3Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany.
4Institute of Pathology, Hannover Medical School, Hannover, Germany.
5Evangelic Bethesda Hospital, Breast Center Niederrhein, Moenchengladbach, Germany; West German Study Group, Moenchengladbach, Germany.
6West German Study Group, Moenchengladbach, Germany; Breast Center, University of Munich (LMU), Munich, Germany.

Abstract
Infiltrating lobular breast cancer (ILBC) is the most common special breast cancer subtype. This review provides a comprehensive description of ILBC characteristics, including epidemiology, clinical features, molecular genetics and histomorphology. Twenty detailed supplemental data tables guide through primary data of more than 200 original studies. Meta-analyses indicate that ILBC is at least twice as common in the Western world as it is in other geographic regions. ILBC is over-represented in so-called interval carcinomas and in primary metastatic breast cancer. ILBC is also associated higher age, higher pT stage and hormone receptor (ER/PR) positivity. Pathological complete response rates after neoadjuvant chemotherapy are low, ranging between 0% and 11%. Positive resection margins after breast-conserving surgery are comparatively frequent and 17% to 65% of patients undergo a second surgical intervention. Depending on the morphological stringency in the diagnosis of ILBC, lack of E-cadherin expression is observed in 55% to 100% of cases. CDH1/E-cadherin mutation detection rates vary between 12% and 83%. Various additional molecular factors, including PIK3CA, TP53, FOXA1, FGFR1, ZNF703 and BCAR4, have been implicated in ILBC or progression of lobular carcinoma in situ (LCIS) to invasive cancer and are discussed in detail. Eight instructive figure plates recapitulate the histomorphology of ILBC and its variants. Furthermore, we draw attention to rarely addressed histological details, such as two-sided nuclear compression and fat-avoiding growth at the invasion front. Last but not least, we discuss future translational research directions and emphasize the concept of synthetic lethality, which promises new options for targeted ILBC therapy.

JohnSmith

Published June 2016:
"Collective Wisdom: Lobular Carcinoma of the Breast"

http://meetinglibrary.asco.org/content/100002-176

This is a decent summary of Lobular. It highlights our current knowledge and reiterates the results from the recent genomic ILC studies.
I'm disappointed that there is no mention of future therapies that may be useful. I expect that the upcoming ILC meeting in Sept 2016 will illuminate therapeutic directions.

Please review and add your thoughts.

CCS648

That is a very good summary. Makes me glad I had a treatment-induced DVT, because otherwise my oncologist would have given me tamoxifen.

I'm really looking forward to seeing what comes out of the conference this fall.

lmnSeattle

Learning about the science of cancer as a whole and ILC specifically is a great way to channel my natural curiosity as I go through treatment. Thank you John for posting such helpful information, including news of the upcoming ILC Conference. I want to learn all I can; make share choices; and advocate for others at risk or a living with ILC.

ng6916832

Something to think about during summer : Gene, molecular, mutation, amplification interpretation is only leading to more and more theoretic research, and may lead one day to a blood test for mutations that will serve in cases of recurrence that will result in a therapy that we might not want to endure.

Pathways, active and non active, are endless and yet not leading to a treatment.

FoundationOne is finding more and more gens to study.

May be a whole other approach is needed

www.novocure.com/

We have a chronic disease, lets face it, despite of better or worse statistics.

Does any here heard about Dr. Castro?

JohnSmith

A member of our Lobular Facebook group posted this onclive.com article from April 2016 which discusses more about the three ILC subtypes.
"Dr. Perou Shares How Deeper Sequencing of Genome Helps Define, Treat Breast Cancer Subtypes"